146 related articles for article (PubMed ID: 37921062)
41. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
[TBL] [Abstract][Full Text] [Related]
42. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
43. The complexity of interpreting genomic data in patients with acute myeloid leukemia.
Nazha A; Zarzour A; Al-Issa K; Radivoyevitch T; Carraway HE; Hirsch CM; Przychodzen B; Patel BJ; Clemente M; Sanikommu SR; Kalaycio M; Maciejewski JP; Sekeres MA
Blood Cancer J; 2016 Dec; 6(12):e510. PubMed ID: 27983727
[TBL] [Abstract][Full Text] [Related]
44. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
45. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
46. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
Eckardt JN; Stasik S; Röllig C; Sauer T; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Herbst R; Hänel M; Hanoun M; Kaiser U; Kaufmann M; Rácil Z; Mayer J; Cerqueira T; Kroschinsky F; Berdel WE; Serve H; Müller-Tidow C; Platzbecker U; Baldus CD; Schetelig J; Siepmann T; Bornhäuser M; Middeke JM; Thiede C
Blood Cancer J; 2023 Jan; 13(1):18. PubMed ID: 36693840
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
[TBL] [Abstract][Full Text] [Related]
48. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
Stengel A; Kern W; Meggendorfer M; Nadarajah N; Perglerovà K; Haferlach T; Haferlach C
Leukemia; 2018 Feb; 32(2):295-302. PubMed ID: 28751771
[TBL] [Abstract][Full Text] [Related]
49. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
51. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].
Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197
[No Abstract] [Full Text] [Related]
52. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
53. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
54. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
[TBL] [Abstract][Full Text] [Related]
55. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
Nagehan P; Sabbir M; Song J; Mohammad H
J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
[TBL] [Abstract][Full Text] [Related]
56. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
[TBL] [Abstract][Full Text] [Related]
57. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL
Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361
[TBL] [Abstract][Full Text] [Related]
58. PCR-Fluo-ASXL1-FA: A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies.
Friedrich C; Zalmaï L; Gay J; Coude MM; Bravetti C; Vazquez R; Temple M; Duroyon E; Darnige L; Decroocq J; Alary AS; Kosmider O
Int J Lab Hematol; 2022 Oct; 44(5):928-933. PubMed ID: 35793805
[TBL] [Abstract][Full Text] [Related]
59. Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group.
Zeng M; Chen K; Tian X; Zou R; Feng X; Li C; Li J; Zheng M; Mai H; Yang L; He Y; Xu H; Wen H; He X
Cancer Med; 2023 Jun; 12(12):13182-13192. PubMed ID: 37132266
[TBL] [Abstract][Full Text] [Related]
60. ASXL1/2 mutations and myeloid malignancies.
Medina EA; Delma CR; Yang FC
J Hematol Oncol; 2022 Sep; 15(1):127. PubMed ID: 36068610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
